CAMBRIDGE, Mass., April 10, 2021 / PRNewswire / – Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company bringing transformative potential from synthetic biology to medicine, today presented data on SYNB1891 for the treatment of solid tumors and lymphomas at the American Association for Cancer Research (AACR Annual Meeting, April 10 to 15, 2021.
The presentation, “Intratumoral injection of SYNB1891, a synthetic biotic designed to activate the innate immune system, demonstrates target engagement in humans, including intratumoral activation of STING”, was delivered by Dr. Filip Janku, Associate Professor, Department of Experimental Cancer Therapy, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. The recording of the presentation will be available for the duration of the conference.
SYNB1891 is an investigational drug being evaluated in an ongoing Phase 1 clinical trial for the treatment of solid tumors and lymphomas. SYNB1891 is composed of a synthetic biotic strain of E. coli Nissle which produces cyclic di-AMP (CDA), a stimulator of the STING pathway (STimulator of INterferon Genes). This mechanism may play a critical role in the initiation of an anti-tumor immune response via the activation of APCs and the presentation of tumor antigens. The results of the monotherapy cohorts include:
- SYNB1891 is safe and well tolerated by intratumoral injection in a heterogeneous population.
- No dose-limiting toxicity or SYNB1891-related infections
- Dose levels across living 1e7 cells demonstrate target engagement as assessed by dose-dependent increases in serum cytokines, upregulation of ISGs, and the presence of tumor infiltrating lymphocytes.
- Evidence of long-lasting stable disease was observed in 2 patients and was associated with upregulation genes related to immune activation and an increase in intratumoral lymphocytes.
These data support continued dose escalation in the monotherapy and combination arms. The study combination arm combines increasing dose levels of SYNB1891 with a fixed dose of a PD-L1 checkpoint inhibitor antibody to establish a recommended phase 2 dose for the combination regimen.
Data from both arms will continue to be reported during 2021, with mature combination therapy data expected by the end of the year.
Learn more about Synlogic’s programs and pipeline by visiting https://www.synlogictx.com/.
SYNB1891 is an investigational drug for the intratumoral treatment of solid tumors and lymphomas, composed of a synthetic biotic strain of E. coli Nissle which produces cyclic di-AMP (CDA), a stimulator of STING (STimulator of INterferon Genes). ) trail. This mechanism may play a critical role in the initiation of an anti-tumor immune response via the activation of APCs and the presentation of tumor antigens. The bacterial chassis of SYNB1891 also stimulates the innate immune system through several other mechanisms, including via Toll-like receptors (TLRs), potentially adding to the magnitude of the overall immune response. While SYNB1891 has been designed with safety features designed to prevent its replication unless supplemented with specific nutrients, the bacteria remain active for several days in the injected tumor to stimulate a local immune response. SYNB1891 is being evaluated in a phase 1 clinical trial (NCT04167137).
Synlogic ™ brings the transformative potential of synthetic biology to medicine. With a world-leading synthetic biology platform that leverages a modular and reproducible approach to microbial engineering, Synlogic designs synthetic biotic drugs that target the underlying biology validated to treat disease in new ways. Synlogic’s proprietary pipeline includes synthetic biologics for the treatment of metabolic disorders including phenylketonuria (PKU) and enteric hyperoxaluria. The company is also building a portfolio of active partners in immunology and oncology.
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for the safe harbor purposes of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release regarding strategy, future operations, clinical development plans, future financial condition, future revenues, projected expenses, outlook, plans and objectives of management are forward-looking statements. In addition, when used in this press release or if used in this press release, the words “may”, “could”, “should”, “expect”, “believe”, “estimate” , “Expect”, “intend”, “plan” “predict” and similar expressions and variations thereof, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements regarding the potential of the Synlogic Platform to develop therapies to treat a wide range of diseases, including: cancer, inborn errors of metabolism and inflammatory and immune disorders; our expectations as to the adequacy of our existing cash balance; the future clinical development of synthetic biotic drugs; the approach adopted by Synlogic to discover and develop new therapies using synthetic biology; and the anticipated timing of Synlogic’s clinical trials on SYNB1891 and the availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement due to various factors, including: uncertainties inherent in the clinical and preclinical development process; Synlogic’s ability to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as the risks identified under the heading “Risk Factors” in the documents filed by Synlogic with the SEC. The forward-looking statements contained in this press release reflect Synlogic’s current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its perspective to change. However, although Synlogic may choose to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be taken as representing the views of Synlogic as of a date subsequent to the date hereof.
SOURCE Synlogic, Inc.